FOLFIRI方案化疗对晚期大肠癌患者的疗效及毒性观察

目的:观察FOLF IR I方案化疗对晚期大肠癌患者的疗效及不良反应。方法:用FOLF IR I方案化疗治疗晚期大肠癌患者76例,其中结肠癌42例,盲肠癌34例,除PD患者外,至少用药3周期,2周期后评价疗效。结果:可评价疗效者76例,无完全缓解(CR)患者,部分缓解(PR)30例,稳定(SD)38例,进展(PD)8例,总有效率(PR+CR)为39.5%,临床受益率为89.5%,中位生存期为14.8个月。主要的不良反应为迟发性腹泻(3/4度为9%)及中性粒细胞减少(3/4度为35%)。结论:对晚期大肠癌患者FOLF IR I方案化疗能够明显提高有效率、延长肿瘤进展时间及改善生存率。

Treatment Response and Adverse Events of FOLFIRI Rigiment in Advanced Coloreetal Cancer Patients

Objective This study was to evaluate the efficacy and safety of FOLFIRI regimen,in treating patients with metastatic colorectal cancer.Methods Seventy-six patients with metastatic colorectal cancer(including 42 colon cancer and 34 rectal cancer) had been treated with FOLFIRI regimen at least 3 cycles,excluding 8 patients(PD).Results There were nocomplete response patients,30 with partial response and 38 with stable disease.The response rate of the whole group was 39.5%.The media survival time was 14.8 months.Dose limiting toxicity was delayed diarrhea(Grade 3/4 cases 9%)and neutropenia(Grade 3/4 cases 35%).Concluslons FOLFIRI regimen could significantly improve response rate,lengthen time to tumor progression and prolong survival.